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Prognostic significance of lung diffusion capacity and spirometric 
parameters in relation to hemodynamic status in heart transplant 
candidates
Abstract
Introduction: Investigations have described a correlation between the severity of heart failure and the severity of pulmonary function 
abnormalities. In this study, we investigated the association of resting spirometric parameters, lung diffusion for carbon monoxide 
(DLCO), and the transfer coefficient (KCO) with hemodynamic variables and outcomes in a cohort of heart transplant candidates.
Material and methods: Between January 2018 and January 2020, a total of 100 patients with advanced heart failure who were 
scheduled for right heart catheterization (RHC) as a pre-transplant evaluation measure were enrolled. Spirometry and DLCO were 
performed in all patients within 24 hours of their RHC. All selected patients were followed for a median (IQR) time of 6 (2–12) 
months. The end points of interest were heart failure-related mortality and a combined event involving HF-related mortality, heart 
transplantation (HTX), and need for the placement of a left ventricular assist device (LVAD).
Results: Among 846 patients scheduled for RHC, a total of 100 patients (25% female) with a mean (SD) age of 38.5 (12.8) were 
enrolled. There was a significant correlation between FEV1/FVC and CVP (r = –0.22, p = 0.02), PCWP (r = –0.4, p < 0.001), 
mPAP (r = –0.45, p < 0.001), and PVR (r = –0.32, p = 0.001). The cardiac output correlated with DLCO (r = 0.3, p = 0.008). 
Spirometry parameters, DLCO parameters, and hemodynamic parameters did not correlate with the combined event. Among the 
several variables, only PVR had an independent association with the combined event.
Conclusion: Both mechanical and gas diffusion parameters of the lung were not associated with outcomes in the homogeneous 
group of heart transplant candidates.
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Introduction
Advances in heart failure (HF) treatment have 
led to an ever-increasing prevalence of end-stage 
heart failure and it is currently considered a pu-
blic health priority in most parts of the world. It 
is estimated that approximately 5–10% of HF pa-
tients have advanced (stage D) heart failure [1, 2]. 
Investigations have thoroughly described 
a correlation between the severity of heart fa-
ilure and the severity of pulmonary function 
abnormalities. Of note, patients with more seve-
re heart failure have more severe abnormalities 
when compared with those who are at earlier 
stages of their disease. The abnormal pulmonary 
capillary hemodynamics in heart failure caused 
by increases in interstitial and alveolar edema 
result in impairment of lung mechanics, resistan-
ce in membrane conductance, and decreased gas 
transfer [3–5]. 
Although both restrictive and obstructive 
patterns have been seen in patients with heart 
failure, the mechanical impairment of the lungs 
in HF is commonly a restrictive lung disease 
shown by a preserved forced expiratory volume 
in one second/forced vital capacity (FEV1/FVC) 
ratio with a progressively lower FEV1, FVC, and 
alveolar volume (VA) as HF severity increases 
[3, 6]. The severity of mechanical impairment 
of the lungs correlates with exercise capacity 
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[5, 7]. Regarding lung diffusion capacity in HF 
measured by lung diffusion for carbon monoxide 
(DLCO), some studies have shown that lung dif-
fusion abnormalities not only correlate with HF 
severity and exercise performance, but also with 
HF prognosis [3, 8–10]. 
The association of spirometric parameters 
and DLCO with hemodynamic status and outcome 
in patients with advanced (stage D) heart failure 
is less clear.
Although some studies investigating the 
prognostic value of spirometry in patients with 
stage C heart failure showed that spirometric 
values predict outcomes in these heart failure 
populations, other studies’ spirometric values 
did not correlate with outcomes in patients with 
advanced heart failure awaiting heart transplanta-
tion [9, 11]. Furthermore, several lines of evidence 
suggest that DLCO abnormalities persist in HF after 
optimal fluid removal or heart transplantation 
[12, 13]. 
In this study, we investigated the association 
of resting spirometric parameters, DLCO, and the 
transfer coefficient (KCO) with hemodynamic 




The study population enrolled included pa-
tients scheduled for right heart catheterization 
(RHC) in our heart failure and transplantation 
department between January 2018 and Janu-
ary 2020 according to the following inclusion/ 
/exclusion criteria.
Inclusion criteria:
— Patients with advanced heart failure accord-
ing to the European Society of Cardiology 
[2] who were scheduled for pre-transplant 
evaluation or left ventricular assist device 
(LVAD) implantation for the first time;
— On optimal guideline-directed medical ther-
apies (GDMT) [2]; 
— Patients who had interagency registry for 
mechanically assisted circulatory support 
(INTERMACS) clinical profiles of 3 (patients 
who are stable but inotrope dependent ) or 
4 (patients who have resting symptoms at 
home on oral therapy) [14]. 
Exclusion criteria:
— Pulmonary disease which may cause obstruc-
tive or restrictive ventilatory defects; 
— Smoker who continued smoking less than 
4 days before the test;
— Anemia (hemoglobin less than 12 g/L);
— Chronic kidney disease with a glomerular 
filtration rate of 60% or less and/or end stage 
renal disease (ESRD) patients;
— Patients who were unable to perform spirom-
etry/DLCO;
— Patients with an INTEMACS profile of 
1 (patients with cardiogenic shock) or 2 (pa-
tients on inotropic support with progressive 
decline) [14]; 
— History of recent heart failure decompensa-
tion in the preceding month;
— Patients with significant pleural effusion. 
The study was approved by the research and 
ethics committee of our institute (Ethics code: 
IR.RHC.REC.1399.081) and written informed 
consent was obtained from all patients. 
Patient evaluations
Right heart catheterization (RHC) was per-
formed via the standard method in all patients 
using a multipurpose A1 catheter in the cathe-
terization laboratory. The pressures were all 
averaged out after 10 consecutive heart beats 
at end expiration in supine position. The follo-
wing variables were measured for each patient: 
mean right atrial pressure (RAP); systolic and 
end-diastolic right ventricular (RV) pressure; 
systolic, diastolic, and mean pulmonary artery 
pressure (mPAP); pulmonary capillary wedge 
pressure (PCWP); mean arterial pressure (MAP); 
and mixed venous oxygen saturation and cardiac 
output (CO) measured by the Fick method. Car-
diac index (CI) was calculated by dividing CO 
by body surface area (BSA). PVR was calculated 
by dividing the transpulmonary gradient (TPG) 
by cardiac output. The transpulmonary gradient 
was calculated by subtracting the mean PAP 
from PCWP. 
Spirometry and DLCO (PFTs) measurements 
are among routine pre-transplantation work ups 
in our center. Spirometry and DLCO measurements 
were performed for all patients using the Gan-
shorn Medizin Electronic pulmonary function te-
sting system with DLCO measurement PowerCube® 
Diffusion+ within 24 hours of their RHC (just 
before RHC in more than 80% of them).
Spirometry was performed with the patient 
in a sitting position using the reproducibility 
and acceptability criteria. Maneuvers were se-
lected according to the American Thoracic So-
ciety/European Respiratory Society (ATS/ERS) 
criteria.15 In this analysis, we considered abso-
lute and percent-of-predicted forced expiratory 
volume in one second (FEV1 and % FEV1), forced 
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vital capacity (FVC and %FVC), and the FEV1/FVC 
ratio. A restrictive ventilatory pattern was defined 
as a combination of FEV1/FVC that was normal or 
more than the 5th percentile (lower limit of normal 
[LLN]) and FVC<LLN with decreased calculated 
total lung capacity. A spirometric obstructive 
ventilatory pattern was defined as a combination 
of FEV1/FVC below the 5th percentile (LLN) and 
FEV1<LLN confirmed by an increased RV size 
with raw and significant reversibility of airway 
obstruction.
DLCO and DLCO corrected for alveolar volume 
(DLCO/VA or KCO) was measured in the standard 
sitting position with the single breath constant 
expiratory flow technique according to the ATS 
recommendations which include rapid inspira-
tion, inspired volume at least 90% of the largest 
vital capacity, breath-hold time between 9 and 
11 seconds, and adequate washout and sample 
volumes [16]. 
The mean of all acceptable tests was con-
sidered. Calculations were standardized for 
breath-hold time and adjusted for dead space, 
gas collection conditions, and carbon dioxide 
concentration.
DLCO was at STPD (standard temperature, 
pressure, and dry) and VA was at BTPS (standard-
ized Body Temperature, Pressure, and Saturation)
The predicted values of DLCO (%DLCO) and 
KCO (%KCO) were calculated using the predictive 
equations for DLCO and KCO derived by Amra et 
al. for the Iranian population [17]. 
Patients’ follow-up and outcome measures
All selected patients were followed after the 
index right heart catheterization until the end 
of July 2020 with a median follow up time of 
6 months. The end points of interest were heart 
failure-related mortality as well as a combined 
event of HF related-mortality, heart transplan-
tation (HTX), and left ventricular assist device 
implantation (LVAD).
Statistical analysis
All analyses were conducted using IBM SPSS 
statistics 22 for Windows (IBM Corp, Armonk, 
NY, USA). One sample Kolmogorov Smirnov test 
was used to assess the normal distribution of 
variables.
Continuous variables with and without nor-
mal distribution are presented as means ± stan-
dard deviation and medians (interquartile range), 
respectively. They were compared using the 
Student’s t-test and the Mann–Whitney U-test, 
as appropriate. Categorical data are presented as 
numbers and percentages and were compared 
by the c2  test. The correlations between spiro-
metric parameters, DLCO, KCO, and hemodyna-
mic parameters were assessed via Spearman’s 
rank correlation coefficient. Stepwise binary 
multiple regression analysis was performed 
to assess the independent correlation between 
spirometric parameters, DLCO, KCO, and hemo-
dynamic findings with the outcome measure. 
All reported probability values were two-tailed 
and a p value < 0.05 was considered statistically 
significant.
Results
Among 846 patients scheduled for RHC, 
a total of 100 patients were enrolled according 
to our inclusion criteria. The mean (SD) age 
of patients was 38.5 (12.8) years. One-fourth 
of the patients were female. More than 90% 
of patients were already on guideline-directed 
medical therapies (GDMT). All of them were 
using loop diuretics, mineralocorticoid receptor 
antagonists (MRA), and angiotensin-converting 
enzyme inhibitors/angiotensin receptor blockers 
(ACEI/ARB). Beta-blockers could not be tolerated 
in 8 patients. The baseline characteristics of pa-
tients and their status at the end of the study are 
summarized in Table 1.
All PFTs were performed within 24 hours of 
RHC. The median (IQR) of the time interval be-
tween RHC and PFTs was 4 (3–5) hours. The PFTs 
were performed less than 6 hours before RHC in 
82% of our study population. In 18% of patients, 
they were performed within 18–24 hours (the day 
before or after RHC).
Table 2 depicts hemodynamic variables and 
spirometry/DLCO parameters. 
Seventy percent (70%) of patients had 
a FEV1 less than 80% of predicted value, 67% of 
patients had a FVC less than 80% of predicted 
value, and all patients had a FEV1/FVC ratio over 
70%. Figure 1 shows the spirometric patterns of 
our study population. Most patients show a re-
strictive ventilatory pattern in their pulmonary 
function tests (PFTs).
Regarding lung diffusion parameters, DLCO 
and KCO were less than 80% of the predicted 
values in 71% and 26% of patients, respectively.
The spirometric and DLCO measurement stu-
dy results did not differ significantly in patients 
with and without a history of smoking. However, 
most cases from the smoker group (90%) involved 
former smokers; only 4 patients were current 
smokers who were smoking occasionally.
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Table 1. Baseline characteristics of patients (n = 100)
Baseline characteristics Value
Age in years, mean [SD] 38.5 (12.8)




BSA, m2, mean [SD] 1.8 (0.2)








LVEF, % median [IQR] 10 (10–20)
Smokers, number [%] 31 (31)
Alcohol overuse, number [%] 21 (21)
DM, number [%] 10 (10)
ICD/CRT, number [%] 45 (45)
GDMT, number [%] 92 (92)
NT-Pro BNP, median [IQR], ng/dl 4926  
(2613–14102)
Serum creatinine mean [SD], mg/dl 1.23 (0.55)
Hemoglubin, mean [SD], g/L 13.1 (2.1)
Intermittent inotrope therapy, 
number [%]
43 (43)
Heart transplantation 38 (38)
LVAD 3 (3)
Heart failure mortality 14 (14)
BNP — brain natriuretic peptide; BSA — body surface area; ICMP — ischemic 
cardiomyopathy; DM — diabetes mellitus; GDMT — guideline-directed medical 
therapy; ICD — implantable cardioverter defibrillator; INTERMACS — Intera-
gency Registry for Mechanically Assisted Circulatory Support; LVAD — left 
ventricular assist device; LVEF — left ventricular ejection fraction




SBP [mm Hg], mean [SD] 103 (15.5)
DBP [mm Hg], mean [SD] 65 (11.5)
HR [beats/min], median [IQR] 95 (81–100)
CVP [mm Hg], mean [SD] 13.6 (7.4)
MPAP [mm Hg], mean [SD] 32 (11)
PADP [mm Hg], mean [SD] 24.7 (9.2)
PCWP [mm Hg], mean [SD] 25.5 (8.5)
Cardiac index [L/min/m2], mean [SD] 1.7 (0.52)
Cardiac output [L/min], mean [SD] 3.3 (0.97)
SVR [WU], median [IQR] 20.3 (16–24.6)
PVR [WU], median [IQR] 2.1 (1.05–3.5)
PFT parameters
FEV1 [L] 2.6 (2.2–3.2)
Percent of predicted FEV1 [%] 71.5 (61–84.2)
FVC [L] 3.2 (2.5–3.8)
Percent of predicted FVC [%] 71 (62–83)
FEV1/FVC 81 (79–83)
DLCO [mL/min/mm Hg] 8.3 (6.7–9.5)
Percent of predicted DLCO [%] 73.9 (63.4–83.2)
KCO [mmol/min/kPa/Lit] 1.85 (1.6–2.1)
Percent of predicted KCO [%] 92.5 (80.2–104)
CVP — central venous pressure; DBP — diastolic blood pressure; DLCO — dif-
fusing capacity of the lungs for carbon monoxide; DPG — diastolic pulmonary 
gradient. FVC — forced vital capacity; FEV1 — forced expiratory volume in one 
second; HR — heart rate; KCO — transfer coefficient of the lung for carbon mo-
noxide; MPAP — mean pulmonary artery pressure; PADP — pulmonary artery 
diastolic pressure; PCWP — pulmonary capillary wedge pressure; PVR — pul-
monary vascular resistance;SBP — systolic blood pressure; SVR — systemic 
vascular resistance; WU — wood units
Association between lung function 
parameters and hemodynamic variables
The Spearman’s rank correlation coefficient 
showed a significant negative correlation between 
FEV1/FVC and CVP (r = -0.22, p = 0.02), PCWP (r 
= -0.4, p < 0.001), mPAP (r = -0.45, p < 0.001), 
and PVR (r = -0.32, p = 0.001).
Cardiac output positively correlated with 
FEV1 (r = 0.2, p = 0.04). There was no association 
found between any of the hemodynamic variables 
and %FEV1, FVC, and %FVC. 
Cardiac output positively correlated with 
DLCO (r = 0.3, p = 0.008) in univariate analysis. No 
correlation was found between %DLCO and the he-
modynamic parameters. The multivariable analy-
sis including LVEF, CO, CI, PCWP, MPAP, PVR, 
history of smoking, diagnosed diabetes mellitus, 
age, and gender showed an independent asso-
ciation between DLCO and CO (b = 0.7, p = 0.03).
Univariate analysis showed that PCWP (for 
both variable r = -0.2, p = 0.03), mPAP (for both 
variable r = -0.3, p = 0.004), PADP (for both 
variable r = -0.2, p = 0.02), and PVR (for both 
variable r = -0.2, p = 0.02) negatively correlated 
with both KCO and %KCO.
The multivariable analysis including the 
variables LVEF, PCWP, MPAP, PVR, history of 
smoking, diagnosed diabetes mellitus, age, and 





Figure 1. The spirometric patterns of our study population (n = 100)
gender showed no independent association be-
tween hemodynamic variables and KCO or %KCO.
Association between PFTs, hemodynamic 
parameters and outcomes
The median (IQR) follow-up duration was 
6 (2–12) months. Outside of 9 patients who had 
a high PVR (more than 5 wood units), the rest of 
the patients were listed for HTX. Due to the very 
limited availability of LVADs in our country, LVAD 
implantation only became possible for 3 patients 
as destination therapy during the follow-up pe-
riod. Heart failure-related mortality was 14%. 
38% of patients were eligible to receive a heart 
transplant. Therefore, the combined event was 
seen in 54% of the study population. 
The median (IQR) amount of time to the 
end-point (HF-related mortality, HTX, or LVAD 
implantation) was 89 days (25–120.5). The time 
to HTX was 31 days (1–108). All of the patients 
who received HTX had an INTERMACS clinical 
profile of 3. The median (IQR) amount of time to 
HF-related mortality was 78 (21–120) days. At the 
end of the follow-up, 45 patients were still alive.
In univariate analyses, neither the spiro-
metric or DLCO measurement parameters (which 
included the PFTs patterns) correlated with the 
combined event. This was also true for the hemo-
dynamic parameters (Figures 2 and 3).
For multivariable analysis, a logistic regres-
sion model with a backward elimination method 
was applied in order to assess the adjusted asso-
ciations between the combined end-point, PFTs, 
and hemodynamic parameters. It was found that, 
among the several variables (which included age, 
gender, %DLCO, %KCO, %FEV1, %FVC, FEV1/FVC 
ratio, PFT patterns, CVP, PCWP, PVR, mPAP, MAP, 
and CI), only PVR had an independent association 
with the combined event (b = 0.25, p = 0.04, Odd 
ratio [95% confidence interval] = 1.3 [1–1.6]). 
Age (p = 0.02), PCWP (p = 0.02), mPAP (p = 
0.02), MAP (p = 0.02), and FEV1/FVC (p = 0.04) 
correlated with HF-related mortality in univariate 
analyses (Figure 4).
Multivariate logistic regression analysis 
showed that only mPAP had an independent 
association with HF-related mortality (b = 0.56, 
p = 0.05, Odd ratio [95% confidence interval] = 
1.7 [1–3]). 
Discussion
In this study, we showed that FEV1/FVC, KCO, 
and %KCO could be correlated with hemodyna-
mic measures in HTX candidates. Among diffe-
rent mechanical and diffusion parameters of lung 
function, only DLCO was independently associated 
with cardiac output in our study population.
Regardless of these associations, neither me-
chanical nor diffusion parameters of pulmonary 
function were predictive of outcomes in HTX 
candidates in the current study.
The relationship between lung function 
values and hemodynamic measures has been 
relatively well explained in patients with HF, 
especially in patients with stage C HF. However, 
data on the importance of pulmonary function 
values in patients with stage D HF (advanced HF) 
have been conflicting [5, 8, 12, 13]. 
In a study by Georgiopoulou et al. [11], the 
spirometric values significantly correlated with 
filling pressures in a cohort of stage D HF patients, 
but none of them were correctly predictive of the 
adverse outcomes. They have also found no asso-
ciation between the functional capacity of HTX 
candidates and their spirometric values.
In a study by Lizak et al. [3], it has also been 
reported that spirometry is not useful for the 
diagnosis and grading of pulmonary diseases in 
HTX candidates. Another study has shown that, 
as symptoms of HF worsen, the influence of spiro-
metric values on functional capacity diminishes.
In a recent study, Deis et al. have shown that 
spirometric values (%FEV1 and %FVC) did not 
correlate with hemodynamics in advanced HF 
patients who were candidates for heart transplan-
tation. Also, their association with adverse out-
comes was not apparent after adjusting for confo-
unding factors [8]. Furthermore, they found that 
central hemodynamics were modestly associated 
with %KCO and that PCWP independently corre-
lated with %KCO in these patients. 
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Figure 2. Comparison of PFT parameters in relation to the combined event. DLCO — diffusing capacity of the lungs for carbon monoxide; FEV1 — 
forced expiratory volume in one second; FVC — forced vital capacity; KCO — transfer coefficient of the lung for carbon monoxide
They also found a significant association 
between KCO and adverse outcomes in a cohort 
of HTX candidates.
There are some differences between our stu-
dy and the study by Deis et al. [8] Although DLCO 
was similarly reduced in our population, we also 
found an association between %KCO and PCWP, 
mPAP, and PVR. However, no association could be 
found between the %KCO and patient outcome.
There are several potential explanations for 
our findings. Our study population was a uniform 
group of HTX candidates who were carefully 
selected from a group of patients with advanced 
HF. Most of them were free of severe end organ 
dysfunction, particularly chronic lung disease, 
which may considerably attenuate the prognostic 
value of PFT results.
One of the strengths of our study was that 
catheterization and PFTs were performed almost 
concurrently. The cardiac and pulmonary sys-
tems are intimately linked physiologically and 
anatomically [18]. As a result, changes in the he-
modynamic status of a patient with HF can have 
profound effects on the pulmonary system which 
can cause abnormalities in PFT parameters. Chan-
ges in hemodynamic status are more frequent in 
patients with advanced heart failure. Therefore, 
the presence of a three-month interval between 
performing PFTs and RHC in the study by Deis 
et al. can make their results less conclusive [8]. 
Furthermore, these pulmonary function ab-
normalities might just indicate that there is a he-
art-lung relationship in this specific population 
of HF patients without providing any underlying 






















































































Figure 3. Comparison of hemodynamic parameters in relation to the combined event. CI — cardiac index; CO — cardiac output; CVP — central 
venous pressure; MPAP — mean pulmonary artery pressure; PCWP — pulmonary capillary wedge pressure; PVR — pulmonary vascular resistance
prognostic importance. Some studies have shown 
that DLCO abnormalities persist after ultrafiltration 
or heart transplantation [5, 13]. Chronic damage 
to the alveolar membrane as a result of long-stan-
ding hemodynamic disturbances in HF can lead to 
decreased DLCO even after optimal HF treatment.
The method of selection of the study popu-
lation and the definition of the outcomes may be 
another reason for the different study results. The 
LVAD is available for a limited number of pa-
tients in our country and because of this, HTX is 
required for the majority of our patients. Many 
patients with an INTERMACS score of 3 will have 
a chance to be given a transplant if there are no 
patients with an INTERMACS clinical profile 
score of 1 or 2. In summary, more than half of our 
patients had met the outcome at the end of our 
short duration follow-up time. As a result, HTX 
or LVAD implantation may not be considered 
as an index event or emergent procedure in our 
population. In fact, this high number of events in 
our cohort in conjunction with a high prevalence 
of PFT abnormalities may be the reason for the 
observed lack of association of PFT values with 
outcomes (rather than the absence of biologic 
association).
Study limitations
Although the careful selection of our study 
population may be a strength of our study, the 
most important limitation of our study and other 
similar studies may be acquiring optimal PFTs in 
patients with advanced HF. The presence of signi-
























































Figure 4. Comparison of PFTs and hemodynamic parameters in relation to heart failure-related mortality. FEV1 — forced expiratory volume in one 
second; FVC — forced vital capacity; MAP — mean arterial pressure; MPAP — mean pulmonary artery pressure; PCWP — pulmonary capillary 
wedge pressure
ficant pulmonary congestion and hypertension, 
sarcopenia, and respiratory muscle weakness can 
make the result of our study suboptimal. 
In summary, although the prognostic signi-
ficance of PFTs in patients with chronic lung 
disease is well known, both mechanical and gas 
diffusion parameters of the lung were not associa-
ted with outcomes in the homogeneous group of 
heart transplant candidates. Advanced and severe 
HF leads to significant changes in lung function 
parameters. Therefore, the usefulness of PFTs to 
diagnose and grade pulmonary function abnor-
malities in this population and the importance of 
pulmonary function abnormalities in heart failure 
survival needs further evaluation.
The duration of HF, the number of decompensa-
tion episodes, and novel heart failure therapies (such 
as medical and surgical neurohormonal modulations) 
all may play a role in the development and progres-
sion of pulmonary abnormalities. This underscores 
the fact that more investigations are needed to find 
definite responses to the remaining questions. 
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